Enrolling by invitationNot applicableNCT06270719
An Observational Study Comparing Delandistrogene Moxeparvovec With Standard of Care in Participants With Duchenne Muscular Dystrophy
Studying Duchenne muscular dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sarepta Therapeutics, Inc.
- Intervention
- Delandistrogene Moxeparvovec(genetic)
- Enrollment
- 500 enrolled
- Eligibility
- 4 years · MALE
- Timeline
- 2024 – 2029
Study locations (20)
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- Children's Hospital Los Angeles - PIN, Los Angeles, California, United States
- University of Colorado - PPDS, Aurora, Colorado, United States
- Connecticut Children's Medical Center - Hartford, Hartford, Connecticut, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Nemours Children's Hospital - Orlando, Orlando, Florida, United States
- All Children's Research Institute, Inc, St. Petersburg, Florida, United States
- Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
- Indiana Clinical and Translational Science Institute, Indianapolis, Indiana, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Duke Lenox Baker Children's Hospital, Durham, North Carolina, United States
- Childrens Hospital Medical Center of Akron, Akron, Ohio, United States
- OHSU Healthcare (Oregon Health and Science University), Portland, Oregon, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06270719 on ClinicalTrials.govOther trials for Duchenne muscular dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07332013Urinary Titin Biomarker in DMDChildren's Hospital of Philadelphia
- RECRUITINGNCT07092540The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular DystrophyUniversity of Rochester
- ENROLLING BY INVITATIONNANCT06887491The Effect of Dual-tasking Program on Cognitive and Physical Functions and Independence in Activities of Daily Living in Children With Duchenne Muscular Dystrophy: A Single-blind Randomized Controlled TrialLokman Hekim University
- ACTIVE NOT RECRUITINGPHASE1NCT07347548A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male ParticipantsGrünenthal GmbH
- ENROLLING BY INVITATIONPHASE2NCT07209332Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular DystrophyWave Life Sciences Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT07282652A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular DystrophyPeking Union Medical College Hospital
- RECRUITINGPHASE2NCT07287189Phase 2 Study of SAT-3247 in Pediatric Ambulatory PatientsSatellos Bioscience, Inc.
- ENROLLING BY INVITATIONNCT07435116Duchenne Muscular Dystrophy and the Viscoelastic Properties of Upper Limb MusclesSanko University